Related Experiment Video
Updated: Jul 23, 2025

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
Published on: July 14, 2023
CA125, Galectin-3 and FGF-23 are interrelated in heart failure with reduced ejection fraction
Damien Gruson1,2, Diane Maisin2, Anne-Catherine Pouleur3
1Pôle de recherche en Endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires St-Luc and Université Catholique de Louvain, Brussels, Belgium.
Background:
Carbohydrate Antigen 125 (CA125) is the most widely used biomarker in ovarian cancer screening. In patients with heart failure (HF), increased levels of CA125 have been observed and related to disease severity. Our objective was to determine the association of CA125 levels with two biomarkers of adverse remodeling in HF patients with reduced ejection fraction (HFrEF).
Methods:
CA125 circulating levels were determined with an electrochemiluminscent immunoassay. Concentrations of B-type natriuretic peptide (BNP), N-terminal proBNP (Nt-proBNP), Galectin-3 and Fibroblast Growth Factor 23 (FGF23) were also measured by immunoassays.
Results:
CA125 levels were increased in HFrEF, were associated to disease severity according NYHA classes. Median CA125 concentration was also significantly related to cardiovascular mortality. CA125 concentrations were positively and significantly associated to Galectin-3 and FGF23.
Conclusions:
Concentrations of CA125 are increased in patients with HFrEF, associated to disease severity and adverse cardiovascular outcomes. CA125 levels are also correlated to Galectin-3 and FGF-23, two biomarkers related to fibrosis and cardiovascular remodeling.
More Related Videos
07:41Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential
Published on: January 18, 2019
06:51Light-sheet Fluorescence Microscopy to Capture 4-Dimensional Images of the Effects of Modulating Shear Stress on the Developing Zebrafish Heart
Published on: August 10, 2018
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure III: Clinical Manifestations
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy